NICOYA年衍药业
/
Back to newsroom
Research updates

Chinese Phase 3 Study of Extended-Release Calcifediol Presented at ASN Kidney Week 2025

NICOYA’s WeChat article highlights a Chinese phase 3 study of extended-release calcifediol presented at ASN Kidney Week 2025.

Research updates

On November 6, 2025, a Chinese phase 3 study of extended-release calcifediol (ERC) was presented as poster TH-PO1192 at ASN Kidney Week. NICOYA covered the study on WeChat on November 10.

The randomized, double-blind, placebo-controlled study enrolled 100 Chinese adults with stage 3 or 4 CKD, vitamin D insufficiency and secondary hyperparathyroidism (SHPT). The 26-week study assessed intact parathyroid hormone, total 25-hydroxyvitamin D and safety outcomes.

This research update does not provide individual treatment advice. Refer to locally approved prescribing information for eligible populations, limitations and safety information.

Reference: ASN Kidney Week 2025, TH-PO1192. DOI: 10.1681/ASN.202556rnsqhc.

View original source年衍药业微信公众号(原文转自丁香园肾脏时间) ↗